Aakaar Medical Technologies Reports Operational Progress for Q1 FY2026-27, Highlights Network Growth and FY27 Guidance

Aakaar Medical Technologies Reports Operational Progress for Q1 FY2026-27, Highlights Network Growth and FY27 Guidance​

Aakaar Medical Technologies Limited has released its operational business update for the first quarter of fiscal year 2026-27 (Q1 FY2026-27), detailing developments across its medical aesthetics ecosystem. The company emphasized strengthening its distribution network, accelerating innovation, and improving commercial discipline as part of its long-term transformation strategy.

The management noted that operational momentum established in the second half of FY26 continued into the current financial year. Aakaar’s objective remains centered on building a high-quality, science driven organization capable of delivering sustainable growth and profitability for stakeholders.

Operational Highlights Q1 FY2026-27​

The operational performance indicators during the quarter demonstrate substantial expansion across key metrics. The company has built out its network while focusing on scientific engagement and execution improvements.

Accelerating Clinic and Distribution Expansion​

The company is actively expanding its clinical footprint. As of the reporting period, 28 XELIX clinics are enrolled across 14 cities, with 21 new clinics onboarded during Q1. Management indicated that 19 clinics were fully branded, and the expansion pipeline continues across critical markets. Aakaar has set ambitious targets, planning to reach 50 clinics in the first half of the financial year and 100 by the end of the second half.

Strengthening the distribution network is another focus area. Novacare Healthcare Solutions was appointed as the national CFA partner. The company has appointed 35 distributors across 24 cities, with migration to the new CFA and distributor model targeted for completion by mid August 2026. The organization is focused on improving receivables, working capital efficiency, and reducing debtor days.

Sales Force Effectiveness and Clinical Reach​

The commitment to growing clinical engagement was demonstrated through significant activity in scientific training and market interaction. More than 45 workshops were conducted, resulting in 308 doctors being trained. The company participated in nine scientific conferences, reaching over 3,100+ dermatologists.

To drive sales force effectiveness, a Sales CRM has been deployed across the 150 field professionals. These representatives are targeting an average of five doctor calls per representative per day, and more than 10,000+ doctor interactions are monitored monthly. Furthermore, continued expansion efforts for LETYBO, SAYPHA, and XOMAGE are underway, with DRS1512 clinical data showing promise in hair fall management during an ongoing clinical trial by dermatologists.

Fiscal Year Outlook and Guidance​

For FY27, the company provided growth guidance, anticipating revenue growth of approximately 30% and EBITDA growth of approximately 25%. The distribution transformation is projected to help improve debtor days to a target range of 120-130 days by the end of FY27.

AAKAAR Stock Price Movement​

Shares of Aakaar Medical Technologies Limited slipped on Friday, settling at ₹71.20 after shedding 4.94% from the previous closing price. The equity registered a traded volume of 4,800 shares during the session.